Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Delphine Béland"'
Autor:
Karen Geoffroy, Bruna Araripe Saraiva, Melissa Viens, Delphine Béland, Marie-Claude Bourgeois-Daigneault
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Proteasome dependency is a feature of many cancers that can be targeted by proteasome inhibitors. For some cancer types, notably breast cancer and triple-negative breast cancer (TNBC), high mRNA expression of a modified form of the proteasom
Externí odkaz:
https://doaj.org/article/2b77bca2eb564e7e9fb4db961860dee6
Autor:
Victor Mullins-Dansereau, Grégory Petrazzo, Karen Geoffroy, Delphine Béland, Marie-Claude Bourgeois-Daigneault
Publikováno v:
OncoImmunology, Vol 8, Iss 11 (2019)
Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration
Externí odkaz:
https://doaj.org/article/905b9199b4cb44f3aafc5b1404ab79e3
Autor:
Marie-Claude Bourgeois-Daigneault, Grégory Petrazzo, Delphine Béland, Karen Geoffroy, Victor Mullins-Dansereau
Publikováno v:
OncoImmunology
OncoImmunology, Taylor & Francis, 2019, 8 (11), pp.e1655363. ⟨10.1080/2162402X.2019.1655363⟩
Oncoimmunology
OncoImmunology, Vol 8, Iss 11 (2019)
OncoImmunology, Taylor & Francis, 2019, 8 (11), pp.e1655363. ⟨10.1080/2162402X.2019.1655363⟩
Oncoimmunology
OncoImmunology, Vol 8, Iss 11 (2019)
Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ef168e4287fbde01f7961b6c140a14
https://hal.archives-ouvertes.fr/hal-02628351
https://hal.archives-ouvertes.fr/hal-02628351